Loading...
XKRX
000227
Market cap54mUSD
Jul 11, Last price  
10,640.00KRW
1D
0.66%
1Q
9.24%
Jan 2017
68.43%
Name

Yuyu Pharma Inc

Chart & Performance

D1W1MN
P/E
19.75
P/S
1.29
EPS
538.87
Div Yield, %
—
Shrs. gr., 5y
1.53%
Rev. gr., 5y
7.94%
Revenues
133.15b
-2.96%
73,393,135,00073,840,117,00045,014,225,00047,900,307,00052,027,334,00058,798,714,33061,984,734,47061,994,114,84062,816,222,71069,743,374,56071,578,932,06062,852,074,31083,096,445,25090,877,644,15098,119,846,400115,655,485,000138,881,056,340137,209,588,670133,147,218,080
Net income
8.72b
P
8,558,432,00013,566,114,000-5,687,375,0002,273,392,0001,117,272,0001,906,768,9002,978,726,7901,876,521,870-7,467,373,380-252,675,0805,885,697,4304,541,420,8104,020,291,0704,722,296,7102,412,605,440-920,289,070-4,425,392,920-7,180,899,6688,720,350,790
CFO
24.95b
+5,828.40%
6,801,053,0003,263,836,00013,074,087,0009,407,251,0005,814,628,0006,673,925,2006,510,487,490-775,171,8001,363,384,420-11,683,508,1609,816,265,2901,335,382,2606,110,025,07013,185,371,370-2,669,008,8204,508,660,900-6,229,000,580420,857,13024,950,108,380
Dividend
Dec 27, 2023110 KRW/sh

Profile

Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, including osteoporosis, brainbone metabolism-hypocalcemia improvement, cerebral and peripheral circulatory disturbance, tromboembolism, respiratory organ, hypertension, pulmonary tuberculosis therapy, arthrifuge, diabetic neuropathy therapy, eczematous dermatitis drugs, and other circulatory system drugs, as well as antibiotics and skeletal muscle relaxants. It also provides non-prescription drugs and health supplements. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Seoul, South Korea.
URL
https://www.yuyu.co.kr/ko/main/main.do
IPO date
Nov 18, 1975
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122017‑032016‑03
Income
Revenues
133,147,218
-2.96%
137,209,589
-1.20%
138,881,056
20.08%
Cost of revenue
102,144,010
111,768,970
114,181,801
Unusual Expense (Income)
NOPBT
31,003,208
25,440,618
24,699,256
NOPBT Margin
23.28%
18.54%
17.78%
Operating Taxes
(304,672)
98,436
615,016
Tax Rate
0.39%
2.49%
NOPAT
31,307,880
25,342,182
24,084,239
Net income
8,720,351
-221.44%
(7,180,900)
62.27%
(4,425,393)
380.87%
Dividends
(2,001,735)
(2,033,747)
Dividend yield
2.33%
1.97%
Proceeds from repurchase of equity
(1,785,236)
BB yield
1.73%
Debt
Debt current
33,241,964
25,386,189
37,424,958
Long-term debt
1,352,758
14,857,429
2,645,227
Deferred revenue
Other long-term liabilities
3,647,286
9,501,573
1,973,690
Net debt
(15,863,318)
1,022,201
8,287,806
Cash flow
Cash from operating activities
24,950,108
420,857
(6,229,001)
CAPEX
(7,112,037)
(4,514,389)
(5,567,721)
Cash from investing activities
(4,008,670)
(2,814,814)
(8,543,848)
Cash from financing activities
(9,860,006)
7,160,246
(9,083,180)
FCF
37,539,825
18,772,143
13,401,797
Balance
Cash
42,649,738
32,354,182
30,777,637
Long term investments
7,808,302
6,867,235
1,004,741
Excess cash
43,800,679
32,360,938
24,838,325
Stockholders' equity
55,822,551
54,847,380
81,951,386
Invested Capital
128,554,409
136,903,443
139,270,382
ROIC
23.59%
18.35%
18.86%
ROCE
17.57%
14.65%
14.72%
EV
Common stock shares outstanding
16,183
16,268
16,581
Price
4,505.00
-14.68%
5,280.00
-15.11%
6,220.00
-20.36%
Market cap
72,902,942
-15.13%
85,894,781
-16.71%
103,131,973
-17.26%
EV
69,463,507
97,677,498
120,570,098
EBITDA
36,669,604
31,047,951
29,726,634
EV/EBITDA
1.89
3.15
4.06
Interest
3,217,984
2,553,778
2,580,742
Interest/NOPBT
10.38%
10.04%
10.45%